Egyesült Államok - angol - NLM (National Library of Medicine)

conopco inc. d/b/a unilever - aluminum zirconium tetrachlorohydrex gly (unii: 8o386558je) (aluminum cation - unii:3xhb1d032b) - aluminum zirconium tetrachlorohydrex gly 18.5 g in 100 g - do not use on broken skin stop use if rash or irritation occurs

Egyesült Államok - angol - NLM (National Library of Medicine)

conopco inc. d/b/a unilever - aluminum zirconium tetrachlorohydrex gly (unii: 8o386558je) (aluminum cation - unii:3xhb1d032b) - aluminum zirconium tetrachlorohydrex gly 18.5 g in 100 g - do not use on broken skin stop use if rash or irritation occurs

Egyesült Államok - angol - NLM (National Library of Medicine)

the dial corporation - aluminum zirconium pentachlorohydrex gly (unii: 94703016sm) (aluminum zirconium pentachlorohydrex gly - unii:94703016sm) - aluminum zirconium pentachlorohydrex gly 16.3 ml in 96.1 ml - use:  reduces underarm perspiration.  extra effective stop use and ask a doctor is rash or irritation occurs. directions:   shake well.  apply to underarms only.

Egyesült Államok - angol - NLM (National Library of Medicine)

pai holdings, llc - aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0), magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p) - aluminum hydroxide 200 mg in 5 ml - for the relief of: - acid indigestion - heartburn - sour stomach - upset stomach due to these symptoms

Egyesült Államok - angol - NLM (National Library of Medicine)

pai holdings, llc - aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0), magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - aluminum hydroxide 400 mg in 5 ml - - acid indigestion - heartburn - sour stomach - upset stomach due to these symptoms - pressure and bloating commonly referred to as gas

Egyesült Államok - angol - NLM (National Library of Medicine)

pai holdings, llc - aluminum hydroxide (unii: 5qb0t2iun0) (aluminum hydroxide - unii:5qb0t2iun0), magnesium hydroxide (unii: nbz3qy004s) (magnesium cation - unii:t6v3lhy838, hydroxide ion - unii:9159uv381p), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - aluminum hydroxide 200 mg in 5 ml - for the relief of: - acid indigestion - heartburn - sour stomach - upset stomach due to these symptoms - pressure and bloating commonly referred to as gas

Egyesült Államok - angol - NLM (National Library of Medicine)

sandoz inc - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate 1.25 mg - dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets (mixed salts of a single entity amphetamine product) is indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. the combined type requires both inattentive and hyperactive-impulsive criteria to be met. in patients known to be hypersensitive to amphetamine, or other components of mixed salts of a single entity amphetamine product. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products (see adverse reactions). patients taking monoamine oxidase inhibitors (maois), or within 14 days of stopping maois (including maois such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis (see warnings and drug interactions). mixed salts of a single entity amphetamine product contains amphetamine, a schedule ii controlled substance. dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction (see warnings and precautions). dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate can be diverted for non‑medical use into illicit channels or distribution. abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with cns stimulants abuse and/or misuse. misuse and abuse of cns stimulants, including dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, can result in overdose and death (see overdosage), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate may produce physical dependence. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of cns stimulants including dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation. dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate may produce tolerance. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

Egyesült Államok - angol - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Egyesült Államok - angol - NLM (National Library of Medicine)

general injectables and vaccines, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Egyesült Államok - angol - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.